RedHill Biopharma (RDHL) Gross Margin (2014 - 2023)
RedHill Biopharma (RDHL) posted quarterly Gross Margin of 55.12% for Q2 2023, up 415.0% year-over-year from 10.7% in Q2 2022, and little changed quarter-over-quarter from 55.21% in Q1 2023.
RedHill Biopharma (RDHL) Gross Margin (2014 - 2023) Analysis & Trends
RedHill Biopharma (RDHL) has reported Gross Margin for 9 consecutive years, with 55.12% the latest figure, recorded in Q2 2023.
- In Q2 2023, Gross Margin rose 415.0% year-over-year to 55.12%; the TTM figure through Jun 2023 stood at 42.74% (up 111.0% YoY), while the FY2025 annual figure was 1927.62%, up 186732.0% from the prior year.
- Gross Margin held at 55.12% in Q2 2023 per RDHL's latest filing, from 55.21% in the prior quarter.
- Across five years, Gross Margin topped out at 75.99% in Q1 2019 and bottomed at 62.41% in Q1 2020.
- Historically, Gross Margin has averaged 43.77% across 5 years, with a median of 50.7% in 2020.
- Annual changes were most pronounced in 2020 — Gross Margin slumped 13840 bps — and 2021, when it soared 11257 bps.
- RedHill Biopharma's Gross Margin stood at 50.44% in 2019, then slipped by 0 bps to 50.37% in 2020, then plunged by 75 bps to 12.4% in 2021, then jumped by 165 bps to 32.82% in 2022, then jumped by 68 bps to 55.12% in 2023.
- Business Quant data shows RDHL's Gross Margin at 55.12% in Q2 2023, 55.21% in Q1 2023, and 32.82% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 55.12% |
| Mar 31, 2023 | 55.21% |
| Dec 31, 2022 | 32.82% |
| Sep 30, 2022 | 46.15% |
| Jun 30, 2022 | 50.97% |
| Mar 31, 2022 | 51.98% |
| Dec 31, 2021 | 12.40% |
| Sep 30, 2021 | 57.29% |
| Jun 30, 2021 | 50.75% |
| Mar 31, 2021 | 50.17% |
| Dec 31, 2020 | 50.37% |
| Sep 30, 2020 | 50.64% |
| Jun 30, 2020 | 32.11% |
| Mar 31, 2020 | -62.41% |
| Dec 31, 2019 | 50.44% |
| Sep 30, 2019 | 55.10% |
| Jun 30, 2019 | 72.81% |
| Mar 31, 2019 | 75.99% |
| Dec 31, 2018 | 57.03% |
| Sep 30, 2018 | 72.89% |